{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447887505
| IUPAC_name = (2''S'',4''S'')-4-(4-Acetyl-1-piperazinyl)-''N''-[(1''R'')-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
| image = Casopitant.svg
| width = 275

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US =
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US =
| legal_status =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| excretion =

<!--Identifiers-->
| CAS_number = 414910-27-3
| CAS_supplemental =
| ATC_prefix = A04
| ATC_suffix = AD13
| PubChem = 23725089
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChEMBL = 2107320
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3B03KPM27L
| ChemSpiderID = 25069049
| KEGG = D06574

<!--Chemical data-->
| C=30 | H=35 | F=7 | N=4 | O=2
| molecular_weight = 616.26 g/mol
| smiles = CC1=C(C=CC(=C1)F)[C@@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
| StdInChI = 1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25-,27+/m1/s1
| StdInChIKey = XGGTZCKQRWXCHW-JRLVAEJTSA-N
| synonyms = <small>(2''R'',4''S'')-4-(4-Acetylpiperazin-1-yl)-''N''-{(1''R'')-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-''N''-methylpiperidine-1-carboxamide</small>
}}

'''Casopitant''' ([[International nonproprietary name|INN]],<ref>{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List56 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL56.pdf | publisher = World Health Organization | accessdate = 17 November 2016 | date = 2006}}</ref>{{rp|208}} tentative trade names '''Rezonic''' ([[United States|U.S.]]), '''Zunrisa''' ([[Europe]])) is an [[Tachykinin receptor 1|neurokinin 1 receptor]] (NK<sub>1</sub>R) [[Receptor antagonist|antagonist]] undergoing research for the treatment of [[chemotherapy-induced nausea and vomiting]] (CINV).<ref>{{cite journal |author=Lohr L |title=Chemotherapy-induced nausea and vomiting |journal=Cancer J |volume=14 |issue=2 |pages=85â€“93 |year=2008 |pmid=18391612 |doi=10.1097/PPO.0b013e31816a0f07 |url=}}</ref> It is currently under development by [[GlaxoSmithKline]] (GSK).

In July 2008, the company filed a marketing authorisation application with the [[European Medicines Agency]]. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.<ref>{{cite web|url=http://www.emea.europa.eu/humandocs/PDFs/EPAR/zunrisa/63959809en.pdf |title=GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa |date=13 October 2009 |publisher=EMEA |accessdate=21 December 2009 |location=London }}{{dead link|date=November 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>

== See also ==
{{colbegin|2}}
* [[NK1 receptor antagonist|NK<sub>1</sub> receptor antagonist]]
* [[Aprepitant]]
* [[Fosaprepitant]]
* [[L-733,060]]
* [[Maropitant]]
* [[Vestipitant]]
{{colend}}

== References ==
{{Reflist|2}}

{{Antiemetics and antinauseants}}
{{Antidepressants}}
{{Anxiolytics}}
{{Neurokinin receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Antiemetics]]
[[Category:NK1 receptor antagonists]]
[[Category:Acetamides]]
[[Category:Piperazines]]
[[Category:Piperidines]]
[[Category:Trifluoromethyl compounds]]
[[Category:Fluoroarenes]]

{{gastrointestinal-drug-stub}}
{{nervous-system-drug-stub}}